IDEAYA Biosciences (NASDAQ:IDYA) pulls back 9.2% this week, but still delivers shareholders solid 23% CAGR over 5 years

Simply Wall St.12-16

It hasn't been the best quarter for IDEAYA Biosciences, Inc. (NASDAQ:IDYA) shareholders, since the share price has fallen 30% in that time. But that doesn't change the fact that the returns over the ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2491066061?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b","is_english":true,"pubTime":"2024-12-16 18:43","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2491066061","market":"us","top_or_hot":-1,"title":"IDEAYA Biosciences (NASDAQ:IDYA) pulls back 9.2% this week, but still delivers shareholders solid 23% CAGR over 5 years","media":"Simply Wall St.","content":"<div>\n<p>It hasn't been the best quarter for IDEAYA Biosciences, Inc. (NASDAQ:IDYA) shareholders, since the share price has fallen 30% in that time. But that doesn't change the fact that the returns over the ...</p>\n\n<a href=\"https://finance.yahoo.com/news/ideaya-biosciences-nasdaq-idya-pulls-104340144.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IDEAYA Biosciences (NASDAQ:IDYA) pulls back 9.2% this week, but still delivers shareholders solid 23% CAGR over 5 years</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIDEAYA Biosciences (NASDAQ:IDYA) pulls back 9.2% this week, but still delivers shareholders solid 23% CAGR over 5 years\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-16 18:43 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/ideaya-biosciences-nasdaq-idya-pulls-104340144.html><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>It hasn't been the best quarter for IDEAYA Biosciences, Inc. (NASDAQ:IDYA) shareholders, since the share price has fallen 30% in that time. But that doesn't change the fact that the returns over the ...</p>\n\n<a href=\"https://finance.yahoo.com/news/ideaya-biosciences-nasdaq-idya-pulls-104340144.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"QLD","symbol_name":"纳指两倍做多ETF","start_time":0,"source_url":"https://finance.yahoo.com/news/ideaya-biosciences-nasdaq-idya-pulls-104340144.html","article_id":"2491066061","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2491066061","pubTimestamp":1734345820,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"It hasn't been the best quarter for IDEAYA Biosciences, Inc.  shareholders, since the share price has fallen 30% in that time. But that doesn't change the fact that the returns over the last five years have been very strong. It's fair to say most would be happy with 187% the gain in that time. Generally speaking the long term returns will give you a better idea of business quality than short periods can. Only time will tell if there is still too much optimism currently reflected in the share price.Since the long term performance has been good but there's been a recent pullback of 9.2%, let's check if the fundamentals match the share price.Check out our latest analysis for IDEAYA Biosciences. IDEAYA Biosciences wasn't profitable in the last twelve months, it is unlikely we'll see a strong correlation between its share price and its earnings per share . Arguably revenue is our next best option. When a company doesn't make profits, we'd generally hope to see good revenue growth. As you ca","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"QLD":"纳指两倍做多ETF","IDYA":"IDEAYA Biosciences","NVIW.SI":"NVDA 3xLongSG261006","BK4585":"ETF&股票定投概念","BK4139":"生物科技","SQQQ":"纳指三倍做空ETF","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","USJW.SI":"ALPHAB 3xLongSG261006","PSQ":"纳指反向ETF","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H",".IXIC":"NASDAQ Composite","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4588":"碎股","USAW.SI":"AMZN 3xLongSG261006","TSYW.SI":"TESLA 3xLongSG261006","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","QID":"纳指两倍做空ETF","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","TQQQ":"纳指三倍做多ETF","NDAQ":"纳斯达克OMX交易所","BK4112":"金融交易所和数据"},"translate_title":"IDEAYA Biosciences（纳斯达克股票代码：IDYA）本周下跌9.2%，但仍为股东带来5年内23%的稳定复合年增长率","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IDYA":1,"NDAQ":1,".IXIC":1,"USJW.SI":0.6,"USAW.SI":0.6,"TSYW.SI":0.6,"TQQQ":0.6,"SQQQ":0.6,"QLD":0.6,"QID":0.6,"PSQ":0.6,"NVIW.SI":0.6,"NQmain":0.6,"MNQmain":0.6},"content_text":"It hasn't been the best quarter for IDEAYA Biosciences, Inc. (NASDAQ:IDYA) shareholders, since the share price has fallen 30% in that time. But that doesn't change the fact that the returns over the last five years have been very strong. It's fair to say most would be happy with 187% the gain in that time. Generally speaking the long term returns will give you a better idea of business quality than short periods can. Only time will tell if there is still too much optimism currently reflected in the share price. \n Since the long term performance has been good but there's been a recent pullback of 9.2%, let's check if the fundamentals match the share price. \n Check out our latest analysis for IDEAYA Biosciences \n IDEAYA Biosciences wasn't profitable in the last twelve months, it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). Arguably revenue is our next best option. When a company doesn't make profits, we'd generally hope to see good revenue growth. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth. \n In the last 5 years IDEAYA Biosciences saw its revenue grow at 18% per year. Even measured against other revenue-focussed companies, that's a good result. Meanwhile, its share price performance certainly reflects the strong growth, given the share price grew at 23% per year, compound, during the period. This suggests the market has well and truly recognized the progress the business has made. IDEAYA Biosciences seems like a high growth stock - so growth investors might want to add it to their watchlist. \n You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image). \n\n\n\n  NasdaqGS:IDYA Earnings and Revenue Growth December 16th 2024\n \n\n IDEAYA Biosciences is a well known stock, with plenty of analyst coverage, suggesting some visibility into future growth. So we recommend checking out this free report showing consensus forecasts \nA Different Perspective\n IDEAYA Biosciences shareholders are down 28% for the year, but the market itself is up 30%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. Longer term investors wouldn't be so upset, since they would have made 23%, each year, over five years. It could be that the recent sell-off is an opportunity, so it may be worth checking the fundamental data for signs of a long term growth trend. It's always interesting to track share price performance over the longer term. But to understand IDEAYA Biosciences better, we need to consider many other factors. For instance, we've identified   3 warning signs for IDEAYA Biosciences  that you should be aware of. \n If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of companies that have proven they can grow earnings. \nPlease note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.\nHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2491066061"}